We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. The Administrator of personal data is STOCKTRADEIQ sp. z o.o., with its registered office in Poznan (61-625), at the following address: Czarna Rola 30 Street. Cookies policy here. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

  • Cookie
    cookieyes-consent
  • Duration
    1 year
  • Description
    CookieYes sets this cookie to remember users' consent preferences so that their preferences are respected on their subsequent visits to this site. It does not collect or store any personal information of the site visitors.
  • Cookie
    x-ms-cpim-csrf
  • Duration
    session
  • Description

    Inter-site request forgery token used to protect crSF. For more information, read the section Token falsification of requests between sites.

  • Cookie
    x-ms-cpim-sso:stocktradeiqauth.onmicrosoft.com_0
  • Duration
    session
  • Description

    Used to support single sign-on sessions. This cookie is set as persistent when the Keep me logged in option is enabled.

  • Cookie
    server-telemetry-{id}
  • Duration
    persistent
  • Description

    A value used by Microsoft for authorisation and authentication.

  • Cookie
    google_auto_fc_cmp_setting
  • Duration
    persistent
  • Description


    Stores the state of the User cookie for the current domain.

     

  • Cookie
    {id}-https://stocktradeiqauth.onmicrosoft.com/{id}
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    msal{id}.active-account
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-refreshtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-idtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    Microsoft Clarity
  • Duration
    1 year
  • Description

    Microsoft Clarity

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

  • Cookie
    isLightMode
  • Duration
    1 year
  • Description

    Defines the UI theme

  • Cookie
    userCultureData
  • Duration
    persistent
  • Description

     Stores information about the user's machine culture.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

  • Cookie
    _ga
  • Duration
    1 year 1 month 4 days
  • Description
    The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
  • Cookie
    _ga_*
  • Duration
    1 year 1 month 4 days
  • Description
    Google Analytics sets this cookie to store and count page views.
  • Cookie
    hotjar
  • Duration
    1 year 1 month 4 days
  • Description

    Analyzing users' behaviour in the website

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

  • Cookie
    __gpi
  • Duration
    1 year 24 days
  • Description
    Google Ads Service uses this cookie to collect information about from multiple websites for retargeting ads.
  • Cookie
    __gads
  • Duration
    1 year 24 days
  • Description

    The file, set by Google, is stored in the DoubleClick domain and tracks the number of times users view an ad, measures the success of the campaign and calculates its revenue. This cookie can only be read from the domain where it is set and does not track any data when browsing other sites.

  • Cookie
    goog:cached:topics
  • Duration
    persistent
  • Description

    It is used to record which adverts have been displayed to the User.

  • Cookie
    IDE
  • Duration
    year
  • Description

    Used by Google DoubleClick to record and report on the Website User's actions after viewing or clicking on an advertiser's ads in order to measure the effectiveness of the ad and present the User with targeted advertising.

  • Cookie
    google_experiment_mod44
  • Duration
    persistent
  • Description

    Used by Google Ad to experiment with the effectiveness of ads on websites using their services.

Powered by Cookieyes logo

    Get Diamond plan for FREE

    logo

    Jasper Therapeutics, Inc. (JSPR)

    Price:

    2.93 USD

    ( - -0.02 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    JSPR
    Name
    Jasper Therapeutics, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    2.930
    Market Cap
    47.620M
    Enterprise value
    242.003M
    Currency
    USD
    Ceo
    Ronald A. Martell
    Full Time Employees
    64
    Website
    jaspertherapeutics.com
    Ipo Date
    2020-01-10
    City
    Redwood City
    Address
    2200 Bridge Pkwy

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    61.122B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    99.014B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Agios Pharmaceuticals, Inc.

    VALUE SCORE:

    12

    Symbol
    AGIO
    Market Cap
    2.262B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -0.686
    P/S
    40.562
    P/B
    1.873
    Debt/Equity
    0.092
    EV/FCF
    -0.107
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    8.744
    Earnings yield
    -1.459
    Debt/assets
    0.046
    FUNDAMENTALS
    Net debt/ebidta
    0.417
    Interest coverage
    0
    Research And Developement To Revenue
    60.971
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.004
    Capex to revenue
    0.321
    Capex to depreciation
    0.235
    Return on tangible assets
    -1.382
    Debt to market cap
    0.045
    Piotroski Score
    0
    FUNDAMENTALS
    PEG
    0.047
    P/CF
    -0.459
    P/FCF
    -0.494
    RoA %
    -138.163
    RoIC %
    -336.862
    Gross Profit Margin %
    -41.823
    Quick Ratio
    2.096
    Current Ratio
    2.096
    Net Profit Margin %
    -5.468k
    Net-Net
    1.101
    FUNDAMENTALS PER SHARE
    FCF per share
    -6.413
    Revenue per share
    0.078
    Net income per share
    -4.274
    Operating cash flow per share
    -6.388
    Free cash flow per share
    -6.413
    Cash per share
    2.630
    Book value per share
    1.564
    Tangible book value per share
    1.564
    Shareholders equity per share
    1.564
    Interest debt per share
    0.143
    TECHNICAL
    52 weeks high
    26.050
    52 weeks low
    2.265
    Current trading session High
    3.050
    Current trading session Low
    2.930
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -4406.231%
    P/E
    -0.696
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.815
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.299
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.346
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.112
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -1.3207188%
    P/E
    -1.658
    DESCRIPTION

    Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

    NEWS
    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jasper-20250817.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    globenewswire.com

    2025-08-17 11:56:00

    NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-20250816.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    prnewswire.com

    2025-08-16 10:00:00

    NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/jasper-therapeutics-reports-second-quarter-2025-financial-results-and-20250813.jpg
    Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    globenewswire.com

    2025-08-13 16:05:00

    REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended June 30, 2025 and provided a corporate update.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jasper-20250813.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    globenewswire.com

    2025-08-13 11:55:00

    NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jasper-20250811.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    prnewswire.com

    2025-08-11 10:00:00

    NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investors-of-jasper-20250809.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    globenewswire.com

    2025-08-09 12:28:00

    NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jasper-20250806.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    prnewswire.com

    2025-08-06 10:00:00

    NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investors-20250801.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    globenewswire.com

    2025-08-01 10:00:00

    NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jasper-20250731.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    prnewswire.com

    2025-07-31 10:00:00

    NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-20250728.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    globenewswire.com

    2025-07-28 11:16:00

    NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jasper-20250727.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    prnewswire.com

    2025-07-27 10:00:00

    NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investors-20250723.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    globenewswire.com

    2025-07-23 10:00:00

    NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jasper-20250722.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    prnewswire.com

    2025-07-22 10:00:00

    NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investors-of-jasper-20250718.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    globenewswire.com

    2025-07-18 12:00:00

    NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jasper-20250717.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    prnewswire.com

    2025-07-17 10:00:00

    NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jasper-20250714.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    globenewswire.com

    2025-07-14 10:00:00

    NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.